All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Battered and bruised Dendreon Corp. has filed for Chapter 11 bankruptcy protection, assuring patients the Seattle company's prostate cancer treatment, Provenge (sipuleucel-T), will remain available as it advances plans to restructure its debt, either through a stand-alone recapitalization or company sale.